Last week, a U.S. Federal Drug Administration advisory panel recommended that the agency approve a new drug called Enbrel. The week before, the full FDA had given the nod to another anti-rheumatoid arthritis drug called Arava. The excitement began with a growing understanding of how rheumatoid arthritis works and doctors are hoping that new treatments may finally succeed in putting one of the worst forms of this painful illness on ice.